Sensei Biotherapeutics, Inc.
General ticker "SNSE" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $218.4M (TTM average)
Sensei Biotherapeutics, Inc. follows the US Stock Market performance with the rate: 27.8%.
Estimated limits based on current volatility of 4.2%: low 10.96$, high 11.91$
Factors to consider:
- Total employees count: 28 as of 2023
- Top business risk factors: Insufficient funding, Product development risks, Market competition, Intellectual property risks, Market volatility
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [5.79$, 16.23$]
- 2025-12-31 to 2026-12-31 estimated range: [5.15$, 14.47$]
Financial Metrics affecting the SNSE estimates:
- Negative: with PPE of -1.5 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -10.61 <= 0.04
- Positive: Shareholder equity ratio, % of 84.62 > 64.17
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Positive: Inventory ratio change, % of 0 <= 0
- Negative: Industry earnings per price (median), % of -16.21 <= 0
Short-term SNSE quotes
Long-term SNSE plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $50.19MM | $37.06MM | $31.66MM |
| Operating Income | $-50.19MM | $-37.06MM | $-31.66MM |
| Non-Operating Income | $1.60MM | $2.96MM | $1.51MM |
| Interest Expense | $0.22MM | $0.14MM | $0.09MM |
| R&D Expense | $30.38MM | $18.30MM | $18.63MM |
| Income(Loss) | $-48.59MM | $-34.10MM | $-30.16MM |
| Profit(Loss)* | $-48.59MM | $-34.10MM | $-30.16MM |
| Stockholders Equity | $103.41MM | $64.89MM | $38.39MM |
| Assets | $118.38MM | $74.37MM | $45.36MM |
| Operating Cash Flow | $-39.03MM | $-32.02MM | $-24.67MM |
| Capital expenditure | $0.32MM | $0.18MM | $0.15MM |
| Investing Cash Flow | $49.95MM | $38.41MM | $22.44MM |
| Financing Cash Flow | $-0.29MM | $-11.17MM | $-0.79MM |
| Earnings Per Share** | $-1.58 | $-1.22 | $-1.20 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.